APA (7th ed.) Citation

K, N., M, S., Y, U., M, T., T, T., N, G., . . . H, I. (2025). HER2DX in older patients with HER2-positive early breast cancer: Extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy. Nature communications, 16(1), 9585. https://doi.org/10.1038/s41467-025-65599-x

Chicago Style (17th ed.) Citation

K, Nozawa, et al. "HER2DX in Older Patients with HER2-positive Early Breast Cancer: Extended Follow-up from the RESPECT Trial of Trastuzumab ± Chemotherapy." Nature Communications 16, no. 1 (2025): 9585. https://doi.org/10.1038/s41467-025-65599-x.

MLA (9th ed.) Citation

K, Nozawa, et al. "HER2DX in Older Patients with HER2-positive Early Breast Cancer: Extended Follow-up from the RESPECT Trial of Trastuzumab ± Chemotherapy." Nature Communications, vol. 16, no. 1, 2025, p. 9585, https://doi.org/10.1038/s41467-025-65599-x.